SAY GOODBYE~~~~~~~~~~~~~~~~~~~~~~~~~~~~~1.20 COMING TOMORROW
Wall street doesn't care about net loss.
Non-GAAP net loss adjusted for certain non-cash or non-recurring items for the first quarter 2013 was $0.17 per share as detailed in the non-GAAP financial results table included in this release.
It is haircut time! That was a big miss and Zohydro pushed back so the FDA can make decisions on other opoids that will make approval harder to achieve.
Currently financial is insignificant. The lost of -.21 to expected -.14 isn't significant enough to drive the stock to 1.20. The financials is already priced in.
The delay of FDA decision is good news to me, as it's possible they are working on REMS.
hope you shorted a huge stack!!!!! LOL
Sentiment: Strong Buy